性激素对致幻剂疗效与耐受性的影响:女性心理健康视角
本文为叙述性综述,综合临床、临床前与神经影像文献,探讨雌二醇与孕酮如何通过药代动力学、药效动力学及大规模脑网络动力学调节致幻剂在女性中的暴露、反应与耐受性。综述指出性激素是致幻剂治疗反应变异中机制上合理但临床表征不足的来源。
要点
- 性激素经胃pH与转运时间、体成分分布及CYP450酶(尤其CYP3A4与CYP2D6)影响致幻剂药代动力学。
- 雌二醇与孕酮动态调节5-HT2A受体密度与结合,低孕酮状态可利用度较高,孕酮优势或低雌激素状态较低。
- 致幻剂主观强度与耐受性可能随激素波动变化,潜在敏感峰值在卵泡早中期与黄体早期,但直接证据有限。
核心结论
- 性激素是致幻剂治疗反应变异中机制上合理、临床相关但表征不足的来源。
研究设计与样本
- 叙述性综述,综合临床、临床前与神经影像文献,考察雌二醇与孕酮对致幻剂药代动力学、药效动力学及大规模脑网络动力学的调节。
主要发现
- 药代动力学层面,性激素影响胃肠道生理(含胃pH与转运时间)、经体成分与体液平衡的组织分布及经CYP450酶调节的肝代谢,尤其CYP3A4与CYP2D6为LSD与裸盖菇素生物转化的关键通路,肾消除作用相对较小。
- 药效动力学层面,雌二醇与孕酮调节5-HT能信号,包括月经周期与生殖寿命中5-HT2A受体密度与结合的动态调节。
- 血小板、PET与SPECT研究提示低孕酮状态5-HT2A可利用度较高,孕酮优势或低雌激素状态可利用度降低。
- 致幻剂还涉及更广泛的5-HT能、谷氨酸能与GABA能系统,汇聚于前额-边缘、默认模式与突显网络,这些环路在抑郁、焦虑与创伤相关障碍中也失调。
- 激素波动可能影响主观强度与耐受性,潜在敏感峰值在卵泡早中期与黄体早期,但直接证据仍有限。
临床怎么用
- 临床评估致幻剂治疗时需考虑女性月经周期、妊娠、产后与绝经等内分泌状态对暴露、反应与耐受性的潜在影响。
局限性
- 致幻剂直接人体数据仍缺失,激素对主观强度与耐受性影响的直接证据有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Women experience a disproportionate burden of affective and stress-related disorders, with symptom variability shaped by endocrine transitions across the menstrual cycle, pregnancy, postpartum, and menopause. Although psychedelic-assisted therapies are increasingly investigated for these conditions, hormonal state represents a largely unaccounted determinant of variability in exposure, response, and tolerability. This narrative review synthesizes clinical, preclinical, and neuroimaging literature to examine how estradiol and progesterone modulate psychedelic pharmacokinetics, pharmacodynamics, and large-scale brain network dynamics implicated in psychiatric disorders. At the pharmacokinetic level, sex hormones influence gastrointestinal physiology (including gastric pH and transit time), tissue distribution via body composition and fluid balance, and hepatic metabolism through modulation of CYP450 enzymes, particularly CYP3A4 and CYP2D6, which are key pathways for LSD and psilocin biotransformation. Renal elimination plays a comparatively minor role. These processes may collectively alter onset, peak concentration, and systemic exposure across hormonal states, although direct human data for psychedelics remain absent. At the pharmacodynamic level, estradiol and progesterone regulate serotonergic signaling, including dynamic modulation of 5-HT2A receptor density and binding across the menstrual cycle and reproductive lifespan. Platelet, PET, and SPECT studies indicate higher 5-HT2A availability in low-progesterone states and reduced availability in progesterone-dominant or hypoestrogenic states. Beyond 5-HT2A, psychedelics engage broader serotonergic, glutamatergic, and GABAergic systems that converge on prefrontal-limbic, default mode, and salience networks, circuits that are also dysregulated across depression, anxiety, and trauma-related disorders. Hormonal fluctuations may further influence subjective intensity and tolerability, with potential sensitivity peaks in the early-mid follicular and early luteal phases, although direct evidence remains limited. Together, these findings suggest sex hormones as a mechanistically plausible, clinically relevant but under-characterized source of variability in psychedelic treatment response.
引用
- Kuypers KPC, Mason NL, Carlier A, et al. Psychedelics and women's mental health: the effects of female sex hormones on psychedelics' efficacy and tolerability. Mol Psychiatry. 2026. PMID: 42552418. doi:10.1038/s41380-026-03801-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。